Emibetuzumab (Anti-HGFR / c-Met)
Emibetuzumab (Anti-HGFR / c-Met) (A2662-GRP)
Products
Description
Emibetuzumab (Anti-HGFR / c-Met) is a humanized bivalent MET antibody targeting both HGF-dependent and HGF-independent MET pathway activation and tumor growth. It can be used in study of cancer. MW :144.56 KD.
Specifications
| Manufacturer | Selleck Chemicals LLC |
|---|---|
| Manufacturer Cat# | A2662 |
| Target | c-Met |